Paper · 40508010
Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer.
Manoukian P and 4 others. Int J Mol Sci, 2025. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer. Papers, record 40508010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40508010
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hedgehog Proteins | Major topic |
| Pancreatic Neoplasms | Major topic |
| Signal Transduction | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Cell Line, Tumor | |
| Stromal Cells | |
| Gene Expression Regulation, Neoplastic | |
| Prognosis | |
| Female | |
| Tumor Microenvironment | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| UVA 2012-5607 | Dutch Cancer Society | PubMed | ||
| 861196 | H2020-MSCA-ITN | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10,984,056 | Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. | Nature | 2000 | https://conductscience.org/library/papers/10984056 | PubMed |
| 2 | 31,941,932 | Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems. | Sci Rep | 2020 | https://conductscience.org/library/papers/31941932 | PubMed |
| 3 | 36,426,859 | Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients. | Carcinogenesis | 2022 | https://conductscience.org/library/papers/36426859 | PubMed |
| 4 | 29,611,542 | Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. | Exp Mol Med | 2017 | https://conductscience.org/library/papers/29611542 | PubMed |
| 5 | 31,197,017 | Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31197017 | PubMed |
| 6 | 23,998,958 | Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma. | Mol Oncol | 2013 | https://conductscience.org/library/papers/23998958 | PubMed |
| 7 | 33,298,926 | TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. | Nat Commun | 2020 | https://conductscience.org/library/papers/33298926 | PubMed |
| 8 | 20,215,540 | Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20215540 | PubMed |
| 9 | 25,359,882 | Blocking Hedgehog release from pancreatic cancer cells increases paracrine signaling potency. | J Cell Sci | 2015 | https://conductscience.org/library/papers/25359882 | PubMed |
| 10 | 31,636,098 | Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31636098 | PubMed |
1 to 10 of 41
See all 41 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,352,291 | The Lysosome-Cathepsin Axis in Pancreatic Cancer: Mechanisms of Stromal Remodeling, Immune Evasion, and Therapy Resistance. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352291 | PubMed |
| 41,394,878 | Epigenetic regulation of the tumor microenvironment in lung cancer: mechanism insights and therapeutic prospects. | Front Immunol | 2025 | https://conductscience.org/library/papers/41394878 | PubMed |
| 41,258,799 | Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. | Cancer Res | 2026 | https://conductscience.org/library/papers/41258799 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SMO | 6,608 | PubTator's text mining | https://conductscience.org/library/genes/6608 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40508010
GET https://conductscience.org/api/papers/v1/40508010/references?page=2